Expert consensus on the use of new anti-hyperglycemic agents to improve cardiovascular and renal outcomes

Atherosclerosis cardiovascular disease（ASCVD） and chronic kidney disease（CKD） are common co-morbidities in patients with type 2 diabetes mellitus（T2 DM）, and associated with higher morbidity and disability. Newly clinical trials showed that certain sodium-glucose cotransporter 2 inhibitors（SGLT2 i） and glucagon-like peptide 1 receptor agonists（GLP-1 RA） could significantly reduce the risk of major adverse cardiovascular events（MACE） in T2 DM patients and had high safety profiles. These new exciting results triggered a major paradigm shift beyond glucose control to a broader strategy of comprehensive cardiovascular and renal risk reduction. The experts group including cardiology, and endocrinology, nephrology and neurology summarized the key beneficial clinical results of the these clinical trials and the potential mechanisms of SGLT2 i and GLP-1 RA, and developed a joint consensus with recommendations to encourage the early initiation and continuous use of the anti-hyperglycemic drugs including SGLT2 i and GLP-1 RA to achieve the improvement of cardiovascular and renal outcomes in patients with T2 DM in the real world routine practice.